Agilent Technologies, Inc. $A Shares Sold by Generali Asset Management SPA SGR

Generali Asset Management SPA SGR lowered its position in shares of Agilent Technologies, Inc. (NYSE:A) by 25.9% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 41,368 shares of the medical research company’s stock after selling 14,422 shares during the quarter. Generali Asset Management SPA SGR’s holdings in Agilent Technologies were worth $4,882,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of A. Brighton Jones LLC boosted its position in Agilent Technologies by 6.1% during the fourth quarter. Brighton Jones LLC now owns 4,663 shares of the medical research company’s stock worth $626,000 after acquiring an additional 270 shares during the last quarter. GAMMA Investing LLC boosted its position in Agilent Technologies by 34.6% during the first quarter. GAMMA Investing LLC now owns 5,362 shares of the medical research company’s stock worth $627,000 after acquiring an additional 1,379 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its position in Agilent Technologies by 86.3% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 51,363 shares of the medical research company’s stock worth $6,009,000 after acquiring an additional 23,800 shares during the last quarter. Ritholtz Wealth Management boosted its holdings in shares of Agilent Technologies by 25.3% in the 1st quarter. Ritholtz Wealth Management now owns 2,953 shares of the medical research company’s stock valued at $345,000 after purchasing an additional 596 shares during the last quarter. Finally, Exchange Traded Concepts LLC boosted its holdings in shares of Agilent Technologies by 6.8% in the 1st quarter. Exchange Traded Concepts LLC now owns 10,941 shares of the medical research company’s stock valued at $1,280,000 after purchasing an additional 701 shares during the last quarter.

Analyst Ratings Changes

A has been the topic of a number of research analyst reports. TD Cowen lifted their price target on shares of Agilent Technologies from $150.00 to $162.00 and gave the company a “buy” rating in a report on Tuesday. JPMorgan Chase & Co. lifted their price target on shares of Agilent Technologies from $155.00 to $165.00 and gave the company an “overweight” rating in a report on Thursday, October 9th. UBS Group upgraded shares of Agilent Technologies from a “neutral” rating to a “buy” rating and lifted their price target for the company from $130.00 to $170.00 in a report on Wednesday, October 8th. Evercore ISI lifted their price target on shares of Agilent Technologies from $128.00 to $140.00 and gave the company an “in-line” rating in a report on Tuesday, October 7th. Finally, Rothschild Redb upgraded shares of Agilent Technologies to a “strong-buy” rating in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, Agilent Technologies presently has a consensus rating of “Moderate Buy” and a consensus price target of $149.62.

Agilent Technologies Stock Performance

NYSE:A opened at $139.14 on Thursday. The company has a current ratio of 2.25, a quick ratio of 1.71 and a debt-to-equity ratio of 0.53. The firm has a market capitalization of $39.45 billion, a price-to-earnings ratio of 32.66, a PEG ratio of 4.51 and a beta of 1.26. The firm’s fifty day simple moving average is $126.49 and its 200 day simple moving average is $117.46. Agilent Technologies, Inc. has a twelve month low of $96.43 and a twelve month high of $153.84.

Agilent Technologies (NYSE:A) last posted its earnings results on Wednesday, August 27th. The medical research company reported $1.37 earnings per share for the quarter, meeting the consensus estimate of $1.37. The business had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.67 billion. Agilent Technologies had a net margin of 17.97% and a return on equity of 25.51%. The business’s quarterly revenue was up 10.1% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.32 EPS. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. As a group, equities research analysts expect that Agilent Technologies, Inc. will post 5.58 earnings per share for the current fiscal year.

Agilent Technologies Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 22nd. Investors of record on Tuesday, September 30th will be paid a dividend of $0.248 per share. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $0.99 annualized dividend and a yield of 0.7%. Agilent Technologies’s payout ratio is 23.24%.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.